K221664 is an FDA 510(k) clearance for the CLEARinse CTS Specimen Collection and Transport System. Classified as Microbial Nucleic Acid Storage And Stabilization Device (product code QBD), Class II - Special Controls.
Submitted by Aardvark Medical, Inc. (Ross, US). The FDA issued a Cleared decision on July 3, 2023 after a review of 390 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.2950 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.
View all Aardvark Medical, Inc. devices